Eli Lilly to study use of arthritis drug to treat COVID-19 [MarketWatch]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketWatch
Eli Lilly and Co. said late Friday it has reached an agreement with the National Institutes of Health to study one of its drugs as a COVID-19 treatment. Baricitinib, marketed as Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis. The study to use it on COVID-19 patients involves those hospitalized because of the illness, and begins this month in the U.S. with a planned expansion to other countries, the company said. The results are expected within the next two months, Eli Lilly said. One of the warnings regarding the use of baricitinib includes the risk of developing serious infections, which could be related to the drug's effects on the immune system. "Given the inflammatory cascade seen in COVID-19, baricitinib's anti-inflammatory activity has been hypothesized to have a potential beneficial effect in COVID-19 and warrants further study in patients with this infection," the company said. Lilly said that b
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Eli Lilly and Company (LLY): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) was given a new $1,200.00 price target on by analysts at BMO Capital Markets.MarketBeat
- Companies Cut Prices For Blockbuster Weight-Loss Drugs [Forbes]Forbes
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/25/25 - Form 4
- LLY's page on the SEC website